Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.

about

Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.

Item

http://www.wikidata.org/entity/Q38724254

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Population Pharmacokinetics of ...... ons for Dosing and Resistance.

@en

type

Item

label

Population Pharmacokinetics of ...... ons for Dosing and Resistance.

@en

prefLabel

Population Pharmacokinetics of ...... ons for Dosing and Resistance.

@en

P1476

Population Pharmacokinetics of ...... ions for Dosing and Resistance

@en

P2093

Kayode Ogungbenro

http://www.w3.org/2001/XMLSchema#string

Muheez Alani Durosinmi

http://www.w3.org/2001/XMLSchema#string

Rahman Ayodele Bolarinwa

http://www.w3.org/2001/XMLSchema#string

Tiwalade Adewale Olugbade

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa.

In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia.

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

P304

1554-1563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.953

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Babatunde A Adeagbo

Oluseye Bolaji

P577

2017-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28618035

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia